[Bendamustine as first line therapy for indolent non-Hodgkin’s lymphoma]
Larrea Bonvento N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001537
Original Title: Bendamustina como primera línea de tratamiento en Linfoma no Hodgkin Indolente
Authors' recommendations: CONCLUSIONS Moderate quality evidence suggests that bendamustine along with rituximab as first line therapy for indolent non-Hodgkin’s lymphoma extends progression-free survival at five years (65.5% vs. 55.5%) when compared with traditional schemes (R-CHOP and R-CVP), although no benefits were observed in overall survival. In addition, no differences in the rate of infections were observed versus other agents. Some clinical practice guidelines include it among the therapeutic alternatives for certain types of lymphoma. Bendamustine has not been approved for this indication (for indolent non-Hodgkin´s lymphoma it has only been approved for refractory or relapsed cases) by any of the regulatory agencies surveyed. No cost-effectiveness or budgetary impact analysis have been found, although its cost is significantly higher than its comparators.
Project Status: Completed
Year Published: 2019
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Lymphoma, Non-Hodgkin
- Antineoplastic Agents, Alkylating
- Bendamustine Hydrochloride
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.